FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track NowZacks Investment Research • 08/27/26
When Inflation Is Sticky, 5 Dividend Aristocrats Are the Stocks to Own Now and Forever24/7 Wall Street • 08/27/26
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseasePRNewsWire • 08/27/26
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?Zacks Investment Research • 08/25/26
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.The Motley Fool • 08/24/26
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer PipelinePRNewsWire • 08/21/26
Billionaire Ken Griffin Increased His Position in This Dividend King by 547%The Motley Fool • 08/19/26
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of SupportPRNewsWire • 08/18/26
Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This YearThe Motley Fool • 08/16/26
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/14/26
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?Zacks Investment Research • 08/14/26
The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is24/7 Wall Street • 08/12/26